medRxiv Preprint Server
April 23, 2022
Alexia G. Aguilar, Burke A. Beauregard, Christopher P. Conroy et al.
2 citations
preprint
Background Ketamine and esketamine are efficacious for treatment resistant depression. Unlike other antidepressants, ketamine and esketamine lack a therapeutic delay and do not increase risk for suicidal thoughts and behaviors in adolescents and young-adults. Esketamine gained FDA approval in March of 2019.
Developmental Psychobiology
July 1, 2014
Brian J. Piper, Christina S. Henderson, Jerrold S. Meyer
2 citations
AbstractIntermittent MDMA pretreatment blocked the reductions in serotonin transporter (SERT) binding induced by an MDMA binge in a prior study in adolescent male rats. The objective of this investigation was to determine if the physiological, behavioral, and neurochemical responses to MDMA are sexually dimorphic. Female Sprague–Dawley rats received MDMA (10 mg/kg × 2) or Saline on every fifth...
Annals of the New York Academy of Sciences
October 1, 2008
Jerrold S. Meyer, Brian J. Piper, Valerie E. Vancollie
44 citations
Adult animals treated with high doses of MDMA (“ecstasy”) either on a single day or for several consecutive days show numerous behavioral changes as well as persistent reductions in brain serotonin (5‐HT) concentrations and 5‐HT transporter (SERT) protein expression. However, such dosing regimens do not adequately mimic the intermittent use patterns commonly seen in adolescent recreational...
Neuropsychopharmacology
April 2008
Brian J. Piper, Joseph B. Fraiman, Cullen B Owens et al.
High or repeated doses of the recreational drug 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy') produce long-lasting deficits in several markers of serotonin (5-HT) system integrity and also alter behavioral function. However, it is not yet clear whether MDMA-induced serotonergic neurotoxicity is responsible for these behavioral changes or whether other mechanisms are involved. The...
Neurotoxicology and Teratology
October 21, 2006
Brian J. Piper
54 citations
The entactogen +/-3,4-methylenedioxymethamphetamine (MDMA or ecstasy) is a popular recreational drug among college, high school, and, occasionally, middle school students. Preclinical research examining the acute and long-term effects of MDMA has predominately been conducted in reproductively mature subjects but there has been increasing interest in adolescent and in utero exposure. This review...
Annals of the New York Academy of Sciences
August 1, 2006
Jerrold S. Meyer, Matthew E. Brevard, Brian J. Piper et al.
40 citations
Abstract: We used functional magnetic resonance imaging (fMRI) to investigate the acute effects of a recreational dose (1 mg/kg p.o.) of 3,4‐methylenedioxymethamphetamine (MDMA) on regional brain activity in awake, restrained marmoset monkeys. In a second study, magnetic resonance spectroscopy (MRS) and postmortem measurements of serotonin transporter (SERT) binding and serotonin (5‐HT)...
Neurotoxicology and Teratology
2006
Brian J. Piper, Jerrold S. Meyer
MDMA [(+/-)3,4-methylenedioxymethamphetamine, also known as ecstasy] is a popular recreational drug among women of reproductive age. The objective of this study was to investigate the long-term neurobehavioral consequences of early developmental MDMA exposure. On postnatal days (PD) 1-4, Sprague-Dawley rats received two 10 mg/kg injections of MDMA with an inter-dose interval of 4 h. Male...
Developmental Psychobiology
2005
Brian J. Piper, Joseph B. Fraiman, Jerrold S. Meyer
71 citations
Previous research in our laboratory found that repeated exposure of adolescent rats to 3,4-methylenedioxymethamphetamine (MDMA) impaired working memory and reduced anxiety. The present experiment extended these findings by investigating the physiological, behavioral, and neurotoxic effects of a modified MDMA treatment regimen. Male Sprague-Dawley rats received 5 mg/kg of MDMA hourly for a...